索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察*

doi:10.3969/j.issn.1672-5069.2020.02.011

摘要/Abstract

摘要： 目的研究应用索磷布韦/维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎(CHC)患者的近期疗效及耐受性。方法 2018年6月～2019年4月收治的58例基因2、3型CHC患者,采用抽签随机法分为两组,每组29例。给予对照组利巴韦林联合干扰素α-2b治疗,观察组接受索磷布韦/维帕他韦联合利巴韦林治疗,两组均持续治疗3个月。采用实时荧光定量聚合酶链反应法检测血清HCV RNA载量,采用基因芯片法检测HCV基因分型。结果观察组快速病毒学应答(RVR)和早期病毒学应答(EVR)率分别为72.4%和89.7%,显著高于对照组的44.8%和65.5%(P＜0.05);在治疗4周末,观察组外周血白细胞计数为(5.8±2.1)×10⁹/L,显著高于对照组【(3.7±1.9)×10⁹/L,P＜0.05】;在治疗12周结束时,观察组外周血白细胞和血小板计数分别为(3.4±0.4)×10⁹/L和(99.60±24.2)×10⁹/L,均显著高于对照组【分别为(2.9±0.9)×10⁹/L和(82.01±14.8)×10⁹/L,P＜0.05】;两组不良反应发生率比较差异无统计学意义(P＞0.05),均未出现终止治疗情况。结论应用索磷布韦/维帕他韦联合利巴韦林治疗基因2、3型CHC患者近期临床疗效确切,安全性较好,值得进一步观察。

关键词: 慢性丙型肝炎, 索磷布韦/维帕他韦, 利巴韦林, 治疗

Abstract: Objective The aim of this study was to investigate the short-term efficacy and tolerance of sofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection. Methods 58 patients with chronic hepatitis C (CHC) and genotype 2 or 3 infection were enrolled in our hospitals from June 2018 through April 2019, and were randomly divided into two groups, 29 in each group. The patients in control group were treated with ribavirin combined with interferonα-2b, and those in the observation group were treated withsofosbuvir/velpatasvir and ribavirin combination. The regimen in the two groups lasted for three months. Serum HCV RNA was detected by RT-PCR, and the viral genotypes was determined by genetic chip sequencing. Results The rapid viralogical response and early viralogical response rates in the observation group were 72.4% and 89.7%, significantly higher than 44.8% and 65.5%(P＜0.05) in the control; at the end of four week treatment, the white blood cell counts in the observation was(5.8±2.1)×10⁹/L, significantly higher than 【(3.7±1.9)×10⁹/L, P＜0.05】 in the control group; at the end of 12 week treatment, the white blood cell count andplatelet count were(3.4±0.4)×10⁹/L and (99.60±24.2)×10⁹/L, both significantly higher than【(2.9±0.9)×10⁹/L and (82.01±14.8)×10⁹/L, respectively, P＜0.05】 in the control group; there was no significantly differences as compared to the side effects in the two groups, and no discontinuation because of severe untoward reactions happened in the two groups. Conclusion The application of sofosbuvir/velpatasvir and bibavirin combination therapyin the treatment of CHC patients with genotype 2 or 3 infection has a good short-term efficacy, which warrants further investigation.

Key words: Hepatitis C, Sofosbuvir/velpatasvir, Ribavirin, Therapy

张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*[J]. 实用肝脏病杂志, 2020, 23(2): 191-194.

Zhang Xiaowei, Zhong Rui. Short-term efficacy and tolerance ofsofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection[J]. Journal of Practical Hepatology, 2020, 23(2): 191-194.

参考文献

[1] 饶慧瑛. 丙型肝炎直接抗病毒治疗研究进展. 实用肝脏病杂志, 2016, 19(4):390-393.
[2] Roux P, Fugon L, Winnock M, et al. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction, 2015, 107(1):152-159.
[3] Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV‐RNA clearance. Am J Transpl, 2015, 3(3):357-360.
[4] Trabaud MA, Bailly F, Si-Ahmed SN, et al. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon. J Med Virol, 2015, 52(1):105-112.
[5] Puenpatom A, Zhang D, Burrell E, et al. Descriptive analysis of drug utilization among chronic hepatitis C virus (CHC) patients in the US commercially insured population. Value Health, 2015, 18(7):A594-A594.
[6] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2015年更新版.实用肝脏病杂志,2016,19(4):ⅠⅩ-ⅩⅩⅤⅠ.
[7] 王瑞, 王学良, 李恒新,等. 西安市吸毒人群HCV感染状况及影响因素分析. 中华疾病控制杂志, 2015, 19(12):1252-1254.
[8] Mazza C, Ravaggi A, Rodella A, et al. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. J Med Virol, 2015, 54(1):12-19.
[9] Hawkins C, Grant J, Ammerman L R, et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. J Antimicrob Chemoth, 2016, 71(9):2642-2645.
[10] Bradshaw D, Lamoury F, Catlett B, et al. A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals. J Infect Dis, 2015, 211(5):736-743.
[11] 唐小琼, 严丽波, 唐红. 服用索非布韦联合利巴韦林治疗慢性丙型肝炎失败后索非布韦联合达卡他韦再治疗成功1例. 中华肝脏病杂志, 2018, 26(5):393-394.
[12] 张琼方, 张大志. 基于索磷布韦的丙型肝炎治疗方案在中国的价值和应用潜力. 中华肝脏病杂志, 2018, 26(3):233-237.
[13] Forlenza JB, Fortier J, Laliberté F, et al. A Descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)-and/or sofosbuvir (SOF)-based regimens: findings from a US payer database. Value Health, 2015, 18(3):A227-A228.
[14] Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (hepnet acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis, 2016, 17(2):215-222.
[15] Walker DR, Pedrosa MC, Manthena SR, et al. Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther, 2015, 32(11):1117-1127.
[16] Origa R, Ponti ML, Filosa A, et al. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol, 2017, 92(12):1349-1355.
[17] Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 2016, 151(1):70-86.
[18] Aggeletopoulou I, Konstantakis C, Manolakopoulos S, et al. Riskof hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol, 2017, 23(24):4317-4323.
[19] Florian J, Mishra P, Arya V, et al. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol Ther, 2015, 98(4):394-402.
[20] Bersoffmatcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. food and drug administration adverse event reporting system. Ann Intern Med, 2017, 166(11):792-798.

索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*

Short-term efficacy and tolerance ofsofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	温博, 王炳元. Wilson’s病:一个潜在的可治疗的遗传性疾病^*[J]. 实用肝脏病杂志, 2020, 23(2): 156-158.
[2]	周翠梅, 胡立芬, 李家斌, 储雪琴, 郜玉峰. 思维导图在慢性乙型肝炎患者管理中应用价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 187-190.
[3]	刘亿军, 段舒馨, 游春芳, 龚科. HFE基因多态性检测判断慢性丙型肝炎患者疾病活动的价值^*[J]. 实用肝脏病杂志, 2020, 23(2): 195-198.
[4]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[5]	王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.
[6]	李永超, 任红军, 刘磊, 张松. 双重血浆吸附联合血浆置换治疗慢加急性乙型肝炎肝衰竭患者临床疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 236-239.
[7]	贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.
[8]	张惠勇, 吴秀欣, 徐成润. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 244-247.
[9]	范建高. 不忘初心,砥励前行[J]. 实用肝脏病杂志, 2020, 23(1): 1-1.
[10]	陈从新, 王莉苹. 应用皮质激素治疗肝衰竭存在什么争议？[J]. 实用肝脏病杂志, 2020, 23(1): 2-3.
[11]	范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握[J]. 实用肝脏病杂志, 2020, 23(1): 7-9.
[12]	纪宇欣, 李树臣. 应用糖皮质激素治疗肝衰竭临床疗效研究进展[J]. 实用肝脏病杂志, 2020, 23(1): 10-13.
[13]	李永华, 孙延芬, 王佳佳, 李艳颖, 于收. 恩替卡韦联合苦参素治疗慢性乙型肝炎患者疗效及其对外周血辅助性T淋巴细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 22-25.
[14]	张健珍, 曾春燕, 张春兰, 许敏, 李剑萍, 李慧慧, 关玉娟. 索非布韦联合达卡他韦治疗慢性丙型肝炎:真实世界临床研究[J]. 实用肝脏病杂志, 2020, 23(1): 30-33.
[15]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.